New Delhi: Despite a huge disease burden, clinical research in India is still on the sidelines. As clinical research is a must for advancing frontiers of health, India urgently needs to substantially augment its share in global clinical research.
This will be the burden of thought churning in 2 day 12th Annual Conference of The Indian Society of Clinical Research (ISCR) starting February 15. Currently India has approximately 20% of the world’s disease burden and yet does less than 1.3% of global clinical research. The high point of ISCR will be Prof V. K Paul, the architect of Ayushman Bharat and Member, NITI Aayog delivering the Prof Ranjit Roy Chaudhury Oration on the inaugural day.
The Indian Society for Clinical Research (ISCR) with its 12th annual conference aims to bring the clinical research community together to learn, connect, and explore opportunities to drive excellence in clinical research. Based on the theme Clinical Research Advancing the Frontiers of Health, the two-day conference is expected to be attended by over 500 delegates from medical institutions, ethics committees, biopharmaceutical industry, government, patient organizations and clinical research organizations.
“Over the last few years, a lot has evolved and continues to evolve in the regulatory environment for clinical research in India. The focus of this year’s Conference will be on how we bring all these reforms cohesively together to build the future research enterprise in the country and address research opportunities emerging in the new environment,” said Dr. Chirag Trivedi, President of ISCR. “Given the growing rate of India’s disease burden, it is essential for us to expand clinical research to facilitate emergence of a solution to the existing health challenges of our country, he added.
The Conference at Hotel Eros will feature two parallel tracks focusing on clinical operations and data management/biostatistics/medical writing. Prior to the annual conference, five pre-conference workshops have been scheduled on February 14thon Clinical Trial Disclosure and Data Transparency, Preparation of Scientific Research Publications, Pharmacovigilance Obligations for MAHs in India, Inspection Readiness and Career Opportunities in Clinical Research.
